DENVER, Colo., Nov 3, 2023 (www.247marketnews.com)- Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported, this morning, preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company’s lead clinical program, WTX-124×2101, from an ongoing, multi-center Phase 1/1b clinical trial of Werewolf’s interleukin 2 (IL-2) INDUKINE molecule, in patients with advanced or metastatic solid tumors. The preliminary data will be presented today at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, California.
Werewolf Therapeutics is trading at $2.70, up $0.55 (+25.6%), on 176.6K premarket shares traded.
Its 52-week range is $1.39 to $4.5687. Its next resistance point is $2.85.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
